This was a full GMP inspection of the entire facility with specific focus on Ondansetron Oral Film drug product
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
The inspection has concluded with four observations
The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
This certification will open new markets for the Kwality Pharma
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Subscribe To Our Newsletter & Stay Updated
